// App-Quantinova.ai

103 : Programmed death-1 blockade in mismatch repair deficient colorectal cancer.

Researchers

Presenter

  • Dung T. Le

Principal Investigators

  • Hao Wang

  • Bjarne Bartlett

  • Holly Kemberling

  • Aleksandra Eyring

  • Nilofer Saba Azad

  • Dan Laheru

  • Ross C. Donehower

  • Todd S. Crocenzi

  • Richard M. Goldberg

  • George A. Fisher

  • James J. Lee

  • Tim F. Greten

  • Minori Koshiji

  • Soon Mo Peter Kang

  • Robert A Anders

  • James R. Eshleman

  • Bert Vogelstein

  • Luis A. Diaz

Medical Centers

  • Johns Hopkins University, Baltimore, MD

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • Johns Hopkins Kimmel Cancer Center, Baltimore, MD

  • Providence Cancer Center, Portland, OR

  • The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital, Columbus, OH

  • University of Pittsburgh, Pittsburgh, PA

  • National Human Genome Research Institute, National Institutes of Health, Bethesda, MD

  • Merck & Co. Inc., Rahway, NJ

  • Johns Hopkins University School of Medicine, Baltimore, MD

Locations

  • United States

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Colorectal Cancer

Biomarkers

  • Programmed cell death protein 1

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • II

Study Id's

  • NCT01876511

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved